Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension

Journal of Human Hypertension

Volumn 19, Issue 2, 2005, Pages 139-144

  Bakris, George L ^a,d   Toto, R D ^b   McCullough, P A ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d Rush Psychiat Clin Research Center   (United States)

Author keywords

ACE inhibitor; Albuminuria; Calcium channel blocker; Diabetic nephropathy; End stage renal disease; Microalbuminuria

Indexed keywords

ALBUMIN; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA RENIN ACTIVITY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENIN-ANGIOTENSIN SYSTEM; RESEARCH DESIGN; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 13544249937     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001789     Document Type: Article

References (18)

1. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2003; 26(Suppl 1): S94-S98.
2. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26(Suppl 1): S80-S82.
3. Garg J, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002; 7: 35-43.
4. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-360.
5. Schmitz A. Microalbuminuria, blood pressure, metabolic control, and renal involvement: longitudinal studies in white non-insulin-dependent diabetic patients. Am J Hypertens 1997; 10 9, Part 2): 189S-197S.
6. Bakris GL, et al, for the RENAAL Study Group. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003; 163: 1555-1565.
7. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
8. Parving H-H, et al, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
9. Lewis EJ, et al, for the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
10. Brenner BM, et al, for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
11. Viberti G, Wheeldon NM, for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
12. Weinberg MS, Kaperonis N, Bakris GL. How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy? Curr Hypertens Rep 2003; 5: 418-425.
13. Bakris GL, et al, for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646-661.
14. Chobanian AV, et al, and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
15. Bakris GL, Weir M. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence? J Clin Hypertens 2002; 4: 420-423.
16. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev 2003; 8: 355-358.
17. National Kidney Foundation. Kidney Disease Outcomes Quality Initiative (K/DOQI). Am J Kidney Dis 2004; 43(5 Suppl 1): S1-S290.
18. Bakris GL, Weir MR. on behalf of the Study of Hypertension and the Efficacy of Lotrel in Diabetes (SHIELD) Investigators. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens 2003; 5: 202-209.